| 8:45-9:00 |
Robert Wiltrout - Welcome |
| |
John Neiderhuber - Opening Comments |
| |
|
|
| 9:00-9:30 |
Tom Waldmann-“The Biology of IL-15
and IL-2: Implications for Cancer Therapy and Vaccine Design” |
| |
|
|
| 9:30-10:00 |
Michael Caligiuri-“The Role of IL-15 in NK Cell Development
and NK Cell Leukemia” |
| |
|
|
| 10:00-10:30 |
Break |
| |
|
|
| 10:30-11:00 |
Francois Villinger-“IL-15
effects in vivo: The view from the healthy and SIV infected nonhuman
primates” |
| |
|
|
| 11:00-11:30 |
Cliff Lane-“The Relative Role of IL-2, 7 & 15 in T Cell
Stimulation” |
| |
|
|
| 11:30-12:00 |
Jay Berzofsky -“The Role of IL-15 as a Vaccine Adjuvant to
Enhance CTL Memory and Avidity and to Replace CD4 Help” |
| |
|
|
| 12:00-1:00 |
Lunch |
| |
|
|
| 1:00-1:30 |
David Weiner-“IL-15 as a DNA Vaccine Adjuvant” |
| |
|
|
| 1:30-2:00 |
Nick Restifo-“Use of IL-15 in the Adoptive Immunotherapy
of Cancer” |
| |
|
|
| 2:00-2:30 |
Bana Jabri- “Control of Effector CTL by IL-15: Role in the
Pathogenesis of Celiac Disease” |
| |
|
|
| 2:30-2:45 |
Break |
| |
|
|
| 2:45-3:45 |
Panel Discussion-“Getting IL-15 to the
Clinic”
- Steve Creekmore
- Micheal Norcross
- Steven A Rosenberg
- Tom Waldmann
- Bob Wiltrout
|
| |
|
|
| |
|
|
